Trius Therapeutics, Inc.

Having one of the industry's largest portfolios of anti-infective drugs allows Merck & Co. Inc. to weather the various storms within this sector of the biopharmaceutical industry, where there is a m

With promising Phase II data now in hand, Cidara Therapeutics Inc. plans to take its lead antifungal candidate, the novel, once-weekly intravenous echinocandin rezafungin acetate (CD-101), into a pa

Impact Biomedicines has closed a structured financing for up to $90m – just two weeks after launching with $22.5m in venture capital – that will support commercialization of its JAK2 inhibitor fedra

Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infect